Accessibility Menu
Orthocell logo

Orthocell(ASX) OCC

Market CapA$216.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+121%
5 Year+49%
1 Year-36%
1 Month-1%
A$0.79
-0.63%
-0.01Today
Orthocell last closing stock price
MetricPriceDate
Last closeAUD 0.792026-08-13
Orthocell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.76%AUD 0.742026-08-06
1 month-0.63%AUD 0.802026-07-14
3 month-5.39%AUD 0.842026-05-15
Year to date-27.19%AUD 1.092025-12-31
1 year-36.29%AUD 1.242025-08-13
3 year+102.56%AUD 0.392023-08-14
5 year+49.06%AUD 0.532021-08-13
Since inception+120.83%AUD 0.362014-08-12

Orthocell Financials at a Glance

Market Cap

A$216.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$15.73M

Net Income (TTM)

-A$15.73M

EPS (TTM)

-A$0.05

P/E Ratio

-15.62

Dividend

A$0.00

Beta (Volatility)

-0.02 (Low)

Price

A$0.79

Volume

0

Open

A$0.81

Previous Close

A$0.79

Daily Range

A$0.79 - A$0.81

52-Week Range

A$0.70 - A$1.60

Estimated Earnings Date

Aug 28, 2026

OCC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Orthocell

Orthocell Limited is a regenerative medicine company based in Murdoch, Australia, focused on developing advanced cell therapies and biological medical devices. Established in 2006, the company aims to facilitate the healing of various bone and soft tissue injuries through innovative products.

Products and Services
  • CelGro: A collagen medical device for surgical repair across multiple indications
  • Ortho-ATI: A specialized cell therapy for chronic tendon injuries
  • Striate+: A biodegradable collagen membrane for dental tissue regeneration
Growth Outlook
  • Recent revenue growth of 36% in the latest quarter indicates strong market demand
  • Expansion into new therapeutic areas is expected to drive future revenue
  • Increased investment in R&D aims to enhance product offerings and market reach
Financial Highlights
  • Latest quarterly revenue of AUD 5.42 million shows significant growth
  • Cash and short-term investments total AUD 44.37 million, providing financial stability
  • Current ratio of 9.17 indicates strong liquidity position
Orthocell Limited is positioned in the biotechnology sector, focusing on innovative solutions for tissue repair and regeneration. The company's flagship products, such as CelGro and Ortho-ATI, are designed to address unmet medical needs in the orthopedic and dental markets. With a robust pipeline and a commitment to research and development, Orthocell is poised for growth as it seeks to expand its market presence and enhance its product portfolio. Recent financial performance reflects a positive trajectory, with increasing revenues and a solid cash position, which may attract potential investors looking for opportunities in the regenerative medicine space.
AI Generated • Jul 21, 2026

Industry

Biotechnology

CEO

Paul Frederick Anderson

Headquarters

Murdoch, WA 6150, AU

OCC Financials

Key Financial Metrics (TTM)

Gross Margin

37.14%

Operating Margin

-180.91%

Net Income Margin

-132.65%

Return on Equity

-44.80%

Return on Capital

-92.27%

Return on Assets

-20.87%

Earnings Yield

-6.40%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$216.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

272.33M

Volume

0

Avg. Volume

328.66K

Financials (TTM)

Gross Profit

A$7.73M

Operating Income

-A$27.97M

EBITDA

-A$24.82M

Operating Cash Flow

-A$19.39M

Capital Expenditure

-A$884.14K

Free Cash Flow

-A$20.27M

Cash & ST Invst.

A$44.37M

Total Debt

A$835.79K

Orthocell Performance Analysis

Orthocell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 1,531,718N/A
20232023-06-30AUD 4,243,069177.0%
20242024-06-30AUD 5,315,37525.3%
20252025-06-30AUD 7,550,68142.1%
Orthocell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3052.9%
Q22024-12-31-38.5%
Q42025-06-3066.1%
Q22025-12-3135.7%
Orthocell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.05N/A
20232023-06-30AUD -0.03-32.3%
20242024-06-30AUD -0.0412.3%
20252025-06-30AUD -0.047.9%
Orthocell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3063.4%
Q22024-12-3137.5%
Q42025-06-30-398.3%
Q22025-12-3129.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$5.42M

+111.8%

Gross Profit

A$1.06M

-40.9%

Gross Margin

19.57%

N/A

Market Cap

A$216.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$5.85M

N/A

Employees

37

N/A

Net Income

-A$5.21M

+0.3%

EBITDA

-A$8.32M

-50.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$44.37M

+126.1%

Total Debt

A$835.79K

+10.0%

Accounts Receivable

A$5.23M

+507.6%

Inventory

A$1.57M

+42.3%

Long Term Debt

A$650.37K

+5.5%

Short Term Debt

A$185.42K

+29.5%

Return on Assets

-20.87%

N/A

Return on Invested Capital

-31.42%

N/A

Free Cash Flow

-A$9.09M

-74.9%

Operating Cash Flow

-A$8.98M

-87.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARX.AXAroa Biosurgery Limited
A$0.59+0.85%
DXB.AXDimerix Limited
A$0.30+1.72%
NYR.AXNyrada Inc.
A$0.71-8.39%
MVF.AXMonash IVF Group Limited
A$0.70+0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.56+0.02%
CDECoeur Mining
$18.45-0.02%
TAT&T
$24.58+0.01%
SMRNuScale Power
$9.85+0.03%

Questions About OCC

What is the current price of Orthocell?

Orthocell is trading at A$0.79 per share.

What is the 52-week range for Orthocell?

Over the past 52 weeks, Orthocell has traded between A$0.70 and A$1.60.

How much debt does Orthocell have?

As of the most recent reporting period, Orthocell reported total debt of A$576.90K.

How much cash does Orthocell have on hand?

Orthocell reported A$28.62M in cash and cash equivalents in its most recent financial results.

What is Orthocell’s dividend yield?

Orthocell does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.